Authors:
van Veen, T
Crusius, JBA
Schrijver, HM
Bouma, G
Killestein, J
van Winsen, L
Pena, AS
Polman, CH
Uitdehaag, BMJ
Citation: T. Van Veen et al., Interleukin-12p40 genotype plays a role in the susceptibility to multiple sclerosis, ANN NEUROL, 50(2), 2001, pp. 275-275
Authors:
de Jong, BA
Schrijver, HM
Huizinga, TWJ
Bollen, ELEM
Polman, CH
Uitdehaag, BMJ
Kersbergen, MC
Sturk, A
Westendorp, RGJ
Citation: Ba. De Jong et al., Innate production of interleukin-10 and tumor necrosis factor affects the risk of multiple sclerosis, ANN NEUROL, 48(4), 2000, pp. 641-646
Authors:
van Boxel-Dezaire, AHH
van Trigt-Hoff, SCJ
Killestein, J
Schrijver, HM
van Houwelingen, JC
Polman, CH
Nagelkerken, L
Citation: Ahh. Van Boxel-dezaire et al., Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: Does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment?, ANN NEUROL, 48(3), 2000, pp. 313-322
Authors:
Killestein, J
Schrijver, HM
Crusius, JBA
Perez, C
Uitdehaag, BMJ
Pena, AS
Polman, CH
Citation: J. Killestein et al., Intracellular adhesion molecule-1 polymorphisms and genetic susceptibilityto multiple sclerosis: Additional data and meta-analysis, ANN NEUROL, 47(2), 2000, pp. 277-278
Authors:
Rep, MHG
Schrijver, HM
van Lopik, T
Hintzen, RQ
Roos, MTL
Ader, HJ
Polman, CH
van Lier, RAW
Citation: Mhg. Rep et al., Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients, J NEUROIMM, 96(1), 1999, pp. 92-100
Citation: Hm. Schrijver et al., Association of interleukin-1 beta and interleukin-1 receptor antagonist genes with disease severity in MS, NEUROLOGY, 52(3), 1999, pp. 595-599